0001179110-22-002947.txt : 20220510
0001179110-22-002947.hdr.sgml : 20220510
20220510170503
ACCESSION NUMBER: 0001179110-22-002947
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220506
FILED AS OF DATE: 20220510
DATE AS OF CHANGE: 20220510
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SEVERINO MICHAEL
CENTRAL INDEX KEY: 0001609447
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35565
FILM NUMBER: 22910874
MAIL ADDRESS:
STREET 1: 1 N. WAUKEGAN ROAD
CITY: NORTH CHICAGO
STATE: IL
ZIP: 60064
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AbbVie Inc.
CENTRAL INDEX KEY: 0001551152
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 320375147
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1 NORTH WAUKEGAN ROAD
CITY: NORTH CHICAGO
STATE: IL
ZIP: 60064
BUSINESS PHONE: (847) 932-7900
MAIL ADDRESS:
STREET 1: 1 NORTH WAUKEGAN ROAD
CITY: NORTH CHICAGO
STATE: IL
ZIP: 60064
4
1
edgar.xml
FORM 4 -
X0306
4
2022-05-06
0
0001551152
AbbVie Inc.
ABBV
0001609447
SEVERINO MICHAEL
1 N. WAUKEGAN ROAD
NORTH CHICAGO
IL
60064
0
1
0
0
Vice Chairman
Common Stock, $0.01 par value
2022-05-06
4
M
0
74309
54.44
A
226412
D
Common Stock, $0.01 par value
2022-05-06
4
M
0
25691
54.86
A
252103
D
Common Stock, $0.01 par value
2022-05-06
4
S
0
40176
150.10
D
211927
D
Common Stock, $0.01 par value
2022-05-06
4
S
0
45988
151.13
D
165939
D
Common Stock, $0.01 par value
2022-05-06
4
S
0
13836
151.78
D
152103
D
Common Stock, $0.01 par value
2022-05-09
4
M
0
66299
54.86
A
218402
D
Common Stock, $0.01 par value
2022-05-09
4
M
0
33701
58.88
A
252103
D
Common Stock, $0.01 par value
2022-05-09
4
S
0
47215
149.53
D
204888
D
Common Stock, $0.01 par value
2022-05-09
4
S
0
31714
150.63
D
173174
D
Common Stock, $0.01 par value
2022-05-09
4
S
0
21071
151.42
D
152103
D
Common Stock, $0.01 par value
2022-05-10
4
M
0
70779
58.88
A
222882
D
Common Stock, $0.01 par value
2022-05-10
4
M
0
29221
61.36
A
252103
D
Common Stock, $0.01 par value
2022-05-10
4
S
0
22873
151.16
D
229230
D
Common Stock, $0.01 par value
2022-05-10
4
S
0
28536
152.24
D
200694
D
Common Stock, $0.01 par value
2022-05-10
4
S
0
48591
152.83
D
152103
D
Option (Right to Buy)
54.44
2022-05-06
4
M
0
74309
54.44
D
2015-06-02
2024-06-01
Common Stock
74309
0
D
Option (Right to Buy)
54.86
2022-05-06
4
M
0
25691
54.86
D
2017-02-18
2026-02-17
Common Stock
25691
66299
D
Option (Right to Buy)
54.86
2022-05-09
4
M
0
66299
54.86
D
2017-02-18
2026-02-17
Common Stock
66299
0
D
Option (Right to Buy)
58.88
2022-05-09
4
M
0
33701
58.88
D
2016-02-19
2025-02-18
Common Stock
33701
70779
D
Option (Right to Buy)
58.88
2022-05-10
4
M
0
70779
58.88
D
2016-02-19
2025-02-18
Common Stock
70779
0
D
Option (Right to Buy)
61.36
2022-05-10
4
M
0
29221
61.36
D
2018-02-16
2027-02-15
Common Stock
29221
70879
D
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.58 to $150.57 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.58 to $151.57 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.58 to $151.95 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.04 to $150.03 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.04 to $151.03 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.04 to $151.93 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.55 to $151.54 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.55 to $152.54 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.55 to $153.50 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.
The option exercise and sale transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).
Steven L. Scrogham, attorney-in-fact for Michael Severino
2022-05-10